The Science
Medicine grounded in evidence, not hype.
A readable map of published GLP-1, peptide, NAD+ biology, metabolic and sexual-wellness research, with direct links to the studies our clinicians care about.
Evidence standard
We separate signal from certainty.
This page is built for physician review and verification: human trial evidence first, preclinical evidence clearly labeled. Every study card links out to the published record.
41
linked publications
7
therapy areas
2
evidence categories
Human trial evidence
Randomized trials and long-term outcome studies carry the most weight when a protocol has direct clinical data.
Preclinical evidence
Animal or in vitro findings are labeled as preclinical and are not presented as proven human benefits.
Biological rationale
How these therapies and cofactors act in the body.
Peptide signaling
Peptides are short chains of amino acids that relay precise instructions between cells and tissues, forming an essential part of how the body's physiology functions.
Compounded precision
Every dose is compounded in 503A and 503B licensed U.S. pharmacies, sterility-tested and calibrated to your individual labs and goals, not a one-size mass-market SKU.
Evidence-led
Protocols draw on peer-reviewed endocrinology, regenerative-medicine and human physiology literature, then narrow decisions through physician review.
Published studies
The literature behind the protocols.
These are not marketing claims. They are starting points for physician review, therapeutic regimen selection and risk discussion. When human trials exist, they are listed before supporting review or preclinical literature, and suggested starting studies sit at the top of each list.
Metabolic care
GLP-1, GIP and glucagon receptor evidence
Human randomized trials anchor the metabolic program. The structure starts with direct weight-loss endpoints, then separates diabetes, established disease-specific outcomes and investigational impacts so patients and clinicians can compare like with like.
Weight-loss endpoints
Tirzepatide Once Weekly for the Treatment of Obesity
New England Journal of Medicine, 2022
SURMOUNT-1 randomized trial in adults with obesity or overweight.
Diabetes-specific endpoints
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
New England Journal of Medicine, 2016
SUSTAIN-6 cardiovascular safety and outcomes trial in type 2 diabetes.
Repair and recovery
Soft-tissue, wound and connective-tissue literature
This category is mostly preclinical. We surface that distinction clearly because animal and cell data are not the same as human outcome trials. Repair protocols are also prescribed alongside graded exercise or rehabilitation of the affected area, because improving blood flow to the healing tissue is part of the therapeutic rationale.
Metabolic cofactor
NAD+ biology and human cofactor literature
NAD+ is a metabolic cofactor essential to cellular energetics. This section presents biochemical and early human physiology literature, not proof of a defined disease-treatment, disease-prevention, metabolic-health or longevity endpoint.
Peptide immunology
Cancer-vaccine and immune-signaling literature
These papers are not treatment claims for Pacific RX protocols. They show how peptide-based signaling can be investigated in rigorous human immunology and oncology settings, including combination strategies with immunotherapy.
Endocrine body composition
Growth-hormone axis and body-composition evidence
Growth-hormone-axis protocols draw from specific endocrine trials and are narrowed through physician review of symptoms, risks, goals and monitoring needs.
Sexual wellness
Melanocortin and hormone-informed care
Sexual-wellness protocols require careful evaluation of regimen fit. The evidence here is strongest for bremelanotide in premenopausal women with acquired generalized HSDD.
Hormone care
Testosterone and menopausal hormone-therapy literature
Hormone protocols are evaluated around symptoms, labs, route, age, risk factors and follow-up. These papers highlight both potential benefit and the need for individualized prescribing.
Clinical translation
Evidence is the beginning of care, not the endpoint.
What the literature can do
It defines biological rationale, expected benefit, known adverse effects, contraindications and monitoring requirements.
What your clinician still decides
Whether a therapy fits your history, labs, medications, goals and state-specific prescribing requirements.
How dosing is approached
Physicians drive the protocol. When a therapy is indicated and prescribed, treatment may start at a minimum dose to assess tolerability before dose changes are considered.
What makes results interpretable
Expectations are benchmarked against a realistic timeline, and medications are paired with diet, exercise or tissue-specific rehabilitation where that is part of the therapeutic rationale.
A careful note
Published does not always mean proven for every patient.
Some therapies have large human trials; others have mainly biology-focused, preclinical or review literature. Pacific RX presents this page as education, not a guarantee of treatment, outcome or prescription.
Browse protocolsHow to read the cards
- Human randomized trials are strongest for patient-facing outcome claims.
- Preclinical studies help explain biological plausibility, not guaranteed human results.
- Review papers help clinicians see patterns, gaps and safety questions across the field.
Retatrutide articles
A closer look at the triple-agonist literature.
Retatrutide is investigational. These articles are included for education and clinical context, not as a guarantee of access, approval or prescribing.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity
New England Journal of Medicine, 2023
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Nature Medicine, 2024
A revolution in obesity treatment
Nature Medicine, 2023
See which protocol fits your biology.
Start with the protocol overview, then complete intake when you are ready for a clinician to review your history.
Browse protocols